Under current guidance, women are referred for further investigation when their CA125 level reaches 35 IU/ml or above, ...
BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...
University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...
The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on ...
Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...
In the future, scientists could use drugs made from cannabis to fight ovarian cancer. A team of scientists testing the ...
Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
Age based thresholds for blood tests to detect ovarian cancer should be introduced, the National Institute for Health and ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback